255 related articles for article (PubMed ID: 35889373)
21. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
22. The mechanism of sitagliptin inhibition of colorectal cancer cell lines' metastatic functionalities.
Varela-Calviño R; Rodríguez-Quiroga M; Dias Carvalho P; Martins F; Serra-Roma A; Vázquez-Iglesias L; Páez de la Cadena M; Velho S; Cordero OJ
IUBMB Life; 2021 May; 73(5):761-773. PubMed ID: 33615655
[TBL] [Abstract][Full Text] [Related]
23. What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands.
Elmansi AM; Awad ME; Eisa NH; Kondrikov D; Hussein KA; Aguilar-Pérez A; Herberg S; Periyasamy-Thandavan S; Fulzele S; Hamrick MW; McGee-Lawrence ME; Isales CM; Volkman BF; Hill WD
Pharmacol Ther; 2019 Jun; 198():90-108. PubMed ID: 30759373
[TBL] [Abstract][Full Text] [Related]
24. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme.
Matteucci E; Giampietro O
Curr Med Chem; 2009; 16(23):2943-51. PubMed ID: 19689275
[TBL] [Abstract][Full Text] [Related]
25. Dipeptidyl peptidase-4 and GLP-1 interplay in STC-1 and GLUTag cell lines.
Kamakura R; Raza GS; Prasannan A; Walkowiak J; Herzig KH
Peptides; 2020 Dec; 134():170419. PubMed ID: 32998057
[TBL] [Abstract][Full Text] [Related]
26. Caveolin-1, a binding protein of CD26, is essential for the anti-inflammatory effects of dipeptidyl peptidase-4 inhibitors on human and mouse macrophages.
Hiromura M; Nohtomi K; Mori Y; Kataoka H; Sugano M; Ohnuma K; Kuwata H; Hirano T
Biochem Biophys Res Commun; 2018 Jan; 495(1):223-229. PubMed ID: 29113797
[TBL] [Abstract][Full Text] [Related]
27. Role of CD26/dipeptidyl peptidase IV in human T cell activation and function.
Ohnuma K; Takahashi N; Yamochi T; Hosono O; Dang NH; Morimoto C
Front Biosci; 2008 Jan; 13():2299-310. PubMed ID: 17981712
[TBL] [Abstract][Full Text] [Related]
28. Dipeptidyl peptidase IV (DPP4) deficiency increases Th1-driven allergic contact dermatitis.
Tasic T; Bäumer W; Schmiedl A; Schwichtenhövel F; Pabst R; Raap U; von Hörsten S; Stephan M
Clin Exp Allergy; 2011 Aug; 41(8):1098-107. PubMed ID: 21672052
[TBL] [Abstract][Full Text] [Related]
29. Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury.
Matheeussen V; Jungraithmayr W; De Meester I
Pharmacol Ther; 2012 Dec; 136(3):267-82. PubMed ID: 22850530
[TBL] [Abstract][Full Text] [Related]
30. The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review.
Melo FJ; Pinto-Lopes P; Estevinho MM; Magro F
Inflamm Bowel Dis; 2021 Jun; 27(7):1153-1165. PubMed ID: 33295607
[TBL] [Abstract][Full Text] [Related]
31. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors.
Chrysant SG; Chrysant GS
Am J Cardiol; 2012 Jun; 109(11):1681-5. PubMed ID: 22425330
[TBL] [Abstract][Full Text] [Related]
32. Regulation and roles of CD26/DPPIV in hematopoiesis and diseases.
Aliyari Serej Z; Ebrahimi Kalan A; Mehdipour A; Nozad Charoudeh H
Biomed Pharmacother; 2017 Jul; 91():88-94. PubMed ID: 28448874
[TBL] [Abstract][Full Text] [Related]
33. The effect of CD26-deficiency on dipeptidyl peptidase 8 and 9 expression profiles in a mouse model of Crohn's disease.
Buljevic S; Detel D; Pugel EP; Varljen J
J Cell Biochem; 2018 Aug; 119(8):6743-6755. PubMed ID: 29693275
[TBL] [Abstract][Full Text] [Related]
34. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
35. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
Tasanen K; Varpuluoma O; Nishie W
Front Immunol; 2019; 10():1238. PubMed ID: 31275298
[TBL] [Abstract][Full Text] [Related]
36. A Physiologically-Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP-1 and GIP and the DPP4 Inhibitor Sitagliptin.
Balazki P; Schaller S; Eissing T; Lehr T
CPT Pharmacometrics Syst Pharmacol; 2020 Jun; 9(6):353-362. PubMed ID: 32543789
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular Effects of Incretin-Based Therapies.
White WB; Baker WL
Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
[TBL] [Abstract][Full Text] [Related]
38. Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones.
Reinhold D; Hemmer B; Gran B; Born I; Faust J; Neubert K; McFarland HF; Martin R; Ansorge S
J Neuroimmunol; 1998 Jul; 87(1-2):203-9. PubMed ID: 9670864
[TBL] [Abstract][Full Text] [Related]
39. A potential contribution of dipeptidyl peptidase-4 by the mediation of monocyte differentiation in the development and progression of abdominal aortic aneurysms.
Lu HY; Huang CY; Shih CM; Lin YW; Tsai CS; Lin FY; Shih CC
J Vasc Surg; 2017 Oct; 66(4):1217-1226.e1. PubMed ID: 27887857
[TBL] [Abstract][Full Text] [Related]
40. An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury.
Ihara M; Asanuma H; Yamazaki S; Kato H; Asano Y; Shinozaki Y; Mori H; Minamino T; Asakura M; Sugimachi M; Mochizuki N; Kitakaze M
Am J Physiol Heart Circ Physiol; 2015 May; 308(10):H1287-97. PubMed ID: 25747753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
